

# What is Incontinence-Associated Dermatitis?

Incontinence-Associated Dermatitis (IAD) is a painful and problematic skin injury that results from exposure to urine or stool. Moisture and irritants trigger inflammation with damage occurring in a "top-down" fashion.<sup>1</sup>

# What is the impact of IAD?

# For you, IAD:

- Creates a poor patient or resident experience
- Increases the burden and cost of care

# For your patient or resident, IAD:


- Is painful
- Increases the risk of complications such as secondary infections and pressure injuries

# Up to 41% of Aged Care residents have IAD<sup>2</sup> LAD is common 43% 43% 43% of all incontinence patients in acute care have IAD<sup>3</sup>

# IAD is a risk factor for pressure injuries.


Incontinence has long been considered a risk factor for pressure injuries – moisture on the skin increases friction and friction is a component of shear force, which can contribute to pressure injury – especially in the

sacrococcygeal area. Recently, IAD has been recognised as a risk factor<sup>4</sup> with the likelihood of developing a pressure injury increasing with the severity of IAD.<sup>5</sup>



# Who is at risk for IAD?

All patients or residents with incontinence are at risk but those with mixed incontinence are the most vulnerable especially when stools are liquid or diarrhoea is present.<sup>6</sup>



# Introducing 3M™ Cavilon™ Continence Care Wipes

A no-rinse cleanser, moisturiser and barrier in a strong yet gentle pre-moistened cloth. This multi-purpose product contains mild surfactants for cleansing along with soothing skin conditioning ingredients.

- · One-step incontinence care helps to reduce caregiver time and effort by combining three steps in one
- Contains moisture repelling dimethicone
- · Hypoallergenic and pH balanced
- Parabens-free, aloe-free and fragrance-free



# The new standard of care.

Evidence suggests that disposable wipes are more effective for prevention of IAD than a skin care regime combining neutral soap and water8. Cavilon Continence Care Wipes are a no-rinse cleanser, moisturiser and barrier in a strong yet gentle pre-moistened cloth. This multipurpose product contains mild surfactants for cleansing along with soothing skin conditioning ingredients. They contain moisture repelling dimethicone (3%). One-step incontinence care helps to reduce caregiver time and effort by combining three steps in one.

Frequent skin cleansing with water and soap is detrimental to skin barrier function by damaging the corneocytes, removing lipids, increasing dryness and creating friction9. Aggressive cleansing technique

(eg using regular washcloths) can increase frictional forces and abrade the skin<sup>10</sup>. Both may contribute to the development of IAD6. Furthermore, infection control issues associated with the use of wash basins have been identified11.

In addition to providing a benefit for skin, use of no-rinse skin cleansers has been shown to save staff time and improve efficiency<sup>12-14</sup>. Continence care wipes are made of smooth material to reduce friction damage. These have been found to enhance adherence to protocols, reduce burden of care and improve staff satisfaction9.

# The Evidence

A defined (structured) skin care regimen, including the use of a soft pre-moistened washcloth impregnated with a 3% dimethicone skin protectant, resulted in a significantly reduced prevalence of IAD and a trend towards less lesions<sup>10</sup>. This study provides evidence supporting the use of a 3-in-1 perineal care washcloth as more effective than standard care including water and a pH neutral soap for IAD prevention and treatment.

# Key elements of an IAD prevention program<sup>6</sup>

Continence care wipes (i.e. 3-in-1 products) that are intended to cleanse, protect and restore may have the advantage of simplifying care by combining products to reduce the number of steps involved, saving clinician/caregiver time and potentially encouraging adherence to the regime 15-17.

1.

# Cleanse

Regular cleansing is critical, but alkaline soaps can disrupt the natural acid mantle of the skin, leading to skin damage. Gentle cleansing with a pH-balanced, no-rinse product removes harmful irritants. Cavilon Continence Care Wipes are pH-balanced.

2.

### **Protect**

An application of a waterproof, durable barrier keeps skin protected through episodes of exposure. Cavilon Continence Care Wipes contain dimethicone for protection from body fluids associated with incontinence. 3.

### Restore

For intact skin, the addition of moisturising ingredients can improve skin health. Cavilon Continence Care Wipes contain moisturising ingredients to help maintain the skin's natural barrier.



ŝ	Principles of CLEANSE in the prevention and management of IAD <sup>6</sup>				
	Principle	Possible with Cavilon Continence Care Wipes			
THE STATE OF THE PERSON NAMED IN	Cleanse daily and after every episode of faecal incontinence	•			
	Use gentle technique with minimal friction, avoid rubbing/scrubbing of skin	•			
ACCH.	Avoid standard (alkaline) soaps	•			
	Choose a gentle, no-rinse liquid skin cleanser or pre-moistened wipe (designed and indicated for incontinence care), with a pH similar to normal skin	•			
	If possible, use a soft, disposable non-woven cloth	•			
	Gently dry skin if needed after cleansing	•			

Spend less time cleaning patients' skin after episodes of incontinence – while you help them feel cleaner, more comfortable and protected.

Cavilon Continence Care Wipes are a convenient, time-saving alternative to plain soap and water. These disposable, hypoallergenic wipes are designed to gently cleanse, moisturise and provide an effective barrier against moisture and bodily fluids. Used regularly, they can be an effective first line of defense against painful and persistent incontinence associated dermatitis (IAD).

# Skin Protection Plan - Managing Incontinence Associated Dermatitis

The best practice principles<sup>6</sup> recommend that for the prevention of IAD, additional skin protection products can be used if extra skin protection is required. For the management of IAD, additional skin protection products can be used if there is worsening erythema/skin condition. We recommend 3M<sup>™</sup> Cavilon<sup>™</sup> Durable Barrier Cream or 3M<sup>™</sup> Cavilon<sup>™</sup> No Sting Barrier Film, depending on the skin condition.

### Cleanse, Moisturise and Protect

### Additional Skin Protectant if worsening erythema/skin condition

Clinical Presentation <sup>1</sup>		What to use	When to use	What to use	When to apply	How much to use
No redness and skin intact (at risk)			After every incontinent episode	Cavion  Cavion  Cavion  Cavion  Cavion  Cavion	Day and night	Pea-size increments
Category 1: Red but skin intact			After every incontinent episode	Cavion Ca	Day and night	Apply an even coat
Category 2: Red with moderate to severe skin breakdown			After every incontinent episode	Cavion  Cavion  Salat Lake Sold Lake	Day and night	Apply an even coat

# **Ordering Information**

Product Code	Product	Size	Items/Pack	Packs/Case
9274	3M™ Cavilon™ Continence Care Wipes	20cm x 30cm	8	12

# For More Information

For more information, please call: 1300 363 878 (Australia) or 0800 80 81 82 (New Zealand) or visit our websites: Cavilon.com.au Cavilon.co.nz

### References

- Thayer DM, Rozenboom B, Baranoski S. "Top-down" Skin Injuries: Prevention and Management of Moisture-Associated Skin Damage, Medical Adhesive-related Skin Injury (MARSI) and Skin Tears. In: Doughty D and McNichol LL eds. Wound Management. Philadelphia, PA Wolters Kluwer 2016. p283.
- Nix D, Haugen V (2010) Prevention and management of Incontinence-Associated Dermatitis. Drugs Aging 27(6): 491-6.
- Gray M, Bartos S. Incontinence-Associated Dermatitis in the Acute Care Setting: A Prospective Multi-Site Epidemiological Study. Presented at the Symposium on Advanced Wound Care. May 2013.
- Beeckman D, Van Lancker A, Van Hecke A, Verhaeghe.S. A systematic review and meta-analysis of Incontinence-Associated Dermatitis, incontinence, and moisture as risk factors for pressure ulcer development. Res NurseHealth 2014;37: 204-18.
- Park KH. The effect of a silicone border foam dressing for prevention of pressure ulcers and Incontinence-Associated Dermatitis in intensive care unit patients. J WOCN 2014; 41(5): 424-29.
- Beeckman D et al. Proceedings of the Global IAD Expert Panel.
   Incontinence-Associated Dermatitis: moving prevention forward. Best Practice Principles. Wounds International 2015.
- 7. 3M data on file
- Doughty D, Junkin J, Kurz P et al. Incontinence-associated dermatitis.
   Consensus statements, evidence-based guidelines for prevention and treatment, current challenges. J WOCN 2012; 39(3): 303-15.
- Beeckman D, Schoonhoven L, Verhaeghe S, et al. Prevention and treatment of incontinence-associated dermatitis: literature review. J Adv Nurs 2009;65(6): 1141-54.
- Beeckman D, Verhaeghe S, Defloor T, et al. A 3-in-1 perine al care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence-associated dermatitis. J WOCN 2011; 38(6): 627-34.
- Johnson D, Lineaweaver L, Maze C. Patients' bath basins as potential sources of infection: a multicenter sampling study. Am J Crit Care Nurses 2009; 8:31-40.
- Beeckman D, DeFloor T, Verhaeghe S, et al. What is the most effective method of preventing and treating incontinence associated dermatitis? Nursing Times 2010; 106(38): 22-25.
- Lewis-Byers K, Thayer D, Kahl A. An evaluation of two incontinence skin care protocols in a long-term care setting. Ostomy Wound Manage 2002; 48(12):44-51.
- Warshaw E, Nix D, Kula J, et al. Clinical and cost-effectiveness of a cleanser protectant lotion for treatment of perineal skin breakdown in low-risk patients with incontinence. Ostomy Wound Manage 2002; 48(6): 44-51
- Gray M, Beeckman D, Bliss DZ, et al. Incontinence-associated dermatitis: a comprehensive review and update. J WOCN 2012; 39(1): 61-74.
- Beeckman D, Woodward S, Gray M. Incontinence-associated dermatitis: step-by-step prevention and treatment. Br J Community Nurs 2011; 16(8): 382-89.
- Driver DS. Perineal dermatitis in critical care patients. Critical Care Nurse 2007; 27(4): 42-46.

